Monoclonal Antibodies in Modern Medicine: Their Therapeutic Potential and Future Directions

The advent of monoclonal antibodies (mAbs) has catalyzed a paradigm shift in therapeutic interventions across a spectrum of diseases. Initially conceived in the 1970s, their development marked a significant milestone in biomedical research, merging principles of immunology with advanced engineering techniques. Monoclonal antibodies, characterized by their specificity for unique antigens, have revolutionized approaches to cancer treatment, enabling personalized medicine that tailors therapies to individual patient profiles. Additionally, their role in managing autoimmune diseases and chronic inflammatory conditions underscores their versatility as therapeutic agents. Despite their remarkable potential, the journey of mAbs is fraught with challenges, including high manufacturing costs and immunogenicity concerns. This exploration endeavors to elucidate the intricate mechanisms of action, therapeutic applications, and future trajectories aimed at optimizing monoclonal antibodies, highlighting their indispensable role in modern medicine and illuminating the path toward innovative healthcare solutions.

Authors

Institutions

Publication Details

Journal
Trends in Pharmaceutical Biotechnology
Published
2024-12-31
DOI
https://doi.org/10.57238/tpb.2024.153196.1019
Citations
10
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
4.04
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Monoclonal Antibodies in Modern Medicine: Their Therapeutic Potential and Future Directions

Samuel Ebele Udeabor
10 citations
Trends in Pharmaceutical Biotechnology
Monoclonal and Polyclonal Antibodies Research
4.04
article

Monoclonal Antibodies in Modern Medicine: Their Therapeutic Potential and Future Directions

Samuel Ebele Udeabor
article en
10 citations

Abstract

The advent of monoclonal antibodies (mAbs) has catalyzed a paradigm shift in therapeutic interventions across a spectrum of diseases. Initially conceived in the 1970s, their development marked a significant milestone in biomedical research, merging principles of immunology with advanced engineering techniques. Monoclonal antibodies, characterized by their specificity for unique antigens, have revolutionized approaches to cancer treatment, enabling personalized medicine that tailors therapies to individual patient profiles. Additionally, their role in managing autoimmune diseases and chronic inflammatory conditions underscores their versatility as therapeutic agents. Despite their remarkable potential, the journey of mAbs is fraught with challenges, including high manufacturing costs and immunogenicity concerns. This exploration endeavors to elucidate the intricate mechanisms of action, therapeutic applications, and future trajectories aimed at optimizing monoclonal antibodies, highlighting their indispensable role in modern medicine and illuminating the path toward innovative healthcare solutions.

Trends in Pharmaceutical BiotechnologyVol. 2(2)
King Khalid University (SA)
Openalex Percentile: Top 6%
Monoclonal and Polyclonal Antibodies Research
4.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.